Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Effect of Y-3 on Repaglinide, Warfarin, and Omeprazole in Healthy Participants
NCT07068841Phase 1Completed
- Sponsor
- NeuroDawn
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of loberamisal, sponsored by NeuroDawn. Primary endpoints: Area Under the Curve from Time Zero to Last Quantifiable Concentration at Day 24 and Area Under the Curve from Time Zero to Infinity at Day 24. Started May 2025; status: completed.
02
Drugs
loberamisal
Beyond the preview
Go deeper on NCT07068841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07068841.